Johnson & Johnson, Procter & Gamble and other manufacturers are arguing that cough and cold drugs with the pain reliever acetaminophen should stay on the market, in spite concerns from U.S. regulators.

The FDA is weighing a ban on combination products, which are often marketed to consumers with colds or other mild illnesses. The industry instead urged a widespread effort to warn buyers about the risks of liver damage linked to the acetaminophen.

Too much acetaminophen has been known to cause liver injury for decades, but FDA officials are worried that the rise of products that combine it with other medications will lead consumers unknowingly to overdose by taking too much of a medication, or by taking too many different products at once.